Comparison of the diagnostic accuracy between 18F-FAPI-04 PET/CT and 18F-FDG PET/CT in the clinical stage IA of lung adenocarcinoma

作者：Han-Xiang Liang, Qi-Wen Huang, Yuemei He, Yuan-Qi Mai, Z.H. Chen, Baoping Wang, Ning Fang, Jianfeng Hu, Li Xie, Ning Zhang, Entao Liu, Xinchun Li · 发表于：Journal of Thoracic Disease · 年份：2025 · DOI：10.21037/jtd-24-1658 · 被引用次数：4 · 研究领域：Peptidase Inhibition and Analysis、Medical Imaging Techniques and Applications、Cancer, Hypoxia, and Metabolism

Background: Fluorine 18-labeled fibroblast activation protein inhibitor (18F-FAPI-04) positron emission tomography/computed tomography (PET/CT) has shown promise for the visualization of advanced stage lung cancer. The accuracy of 18F-FAPI-04 compared with that of fluorine-18 labeled-fluorodeoxyglucose (18F-FDG) in detecting early lung adenocarcinoma (LUAD) remains unknown. Taking the surgical pathology of pulmonary nodule as the gold standard, the diagnostic performance of stage IA LUAD were compared between 18F-FAPI-04 PET/CT and 18F-FDG PET/CT, and the correlation between 18F-FAPI-04 uptake and pathological characteristics of stage IA LUAD. Methods: This prospective study from February 2023 to October 2023 analyzed patients with stage IA LUAD who underwent simultaneous examinations with 18F-FAPI-04 and 18F-FDG PET/CT. Semi-quantitative parameters such as maximum standardized uptake value (SUVmax), tumor-to-background ratio (TBR), metabolic tumor volume (MTV), total lesion glycolysis (TLG), FAPI avid tumor volume (FTV), and total lesion FAP expression (TLF) were calculated. The two patterns were compared using either a paired Student’s t-test or a Wilcoxon signed-rank test. Immunohistochemical (IHC) staining for detecting fibroblast activating protein (FAP) expression was performed in all resected tumor specimens. Correlation analysis was performed between 18F-FAPI-04 uptake and pathological features of stage IA LUAD. Results: A total of 20 patients diagnosed with stage IA ...